Outcomes Among Acute Heart Failure Emergency Department Patients by Preserved vs. Reduced Ejection Fraction
Dana R. Sax(Kaiser Permanente), Dustin G. Mark(Kaiser Permanente), Jie Huang(Kaiser Permanente), Alan B. Storrow(Vanderbilt University Medical Center), Sean P. Collins(Mayo Clinic), Jamal S. Rana(Kaiser Permanente), Mary E. Reed(Kaiser Permanente), Dandan Liu(Vanderbilt University Medical Center)
Cited by 12
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2020|485
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
|European Heart Journal|2022|213
Soluble guanylate cyclase: a potential therapeutic target for heart failure
|Heart Failure Reviews|2012|155